CO-RADIA
18.7.2024 15:01:36 CEST | Business Wire | Press release
Three aerospace leaders – Aernnova, Leonardo and AFuzion – will partner with Radia on WindRunner™, the world’s largest aircraft. Radia is developing WindRunner to deliver the largest, most efficient wind turbine blades, expand the reach of wind energy and transform its economics, enabling the world to meet its climate goals.
The companies are joining Radia’s innovation ecosystem. They will be available to discuss the partnerships at the 2024 Farnborough International Airshow.
Aernnova will partner with Radia on the development of the aircraft’s wing and engine pylons. Leonardo will develop the fuselage. AFuzion will provide safety and certification consulting.
The partnership agreements are the latest step forward for WindRunner, an aircraft designed for its primary mission: To fly large turbine blades – up to 105m in length, longer than a football pitch – directly to wind farm sites, landing on semi-prepared dirt runways as short as 1,800m (6,000 ft). It will overcome logistical barriers that today prevent the expansion of onshore wind energy. Wind turbines become more effective and efficient the larger they are. But long turbine blades are extremely difficult and expensive to move by ground transport because literal roadblocks – bridges, tunnels and road curves – get in the way.
WindRunner will fly over these roadblocks, enabling the deployment of the largest, most efficient onshore wind turbines today and the even larger ones of the future – what Radia calls GigaWind™.
The result will be widespread availability of consistent, lowest-cost clean energy in more locations and at industrial scale for the grid, green fuel production including sustainable aviation fuel (SAF), and commercial power users such as data centers and hyperscalers. The market for onshore wind energy is estimated at up to $10 trillion by 2050 – as many as 1 million wind turbines.
Partners Will Help Radia Fulfill Its Mission and Can Seize a New Opportunity for Aerospace
“WindRunner is an opportunity for the aerospace industry to have a decisive impact on climate change, diversify into the energy industry and seize an enormous market opportunity,” said Mark Lundstrom, Radia’s CEO. “We are extremely pleased and excited that Aernnova, Leonardo and AFuzion – three companies at the forefront of aerospace design, development, and engineering – have chosen to partner with us on this critically important project.”
Partners Attracted by Scope and Ambition of Project, Importance of its Goals, Say Aernnova, Leonardo and AFuzion Executives
“We are excited and proud to participate in the world’s largest aircraft, especially in view of its mission,” said Ricardo Chocarro, CEO of Aernnova. “Based on my previous experience in this sector of the wind turbine industry, I can affirm the importance of the solution that WindRunner provides. The agreement with Radia for the development of the WindRunner project positions us in the wing and engine pylon design and manufacturing support, recognizing our expertise for the design and development of this ambitious project.”
Stefano Bortoli, Leonardo Aerostructures Division MD, said: “The WindRunner initiative is an interesting example of how the aerospace industry continues to provide a key contribution to sustainability, with a range of diversified solutions to the benefit of multiple sectors. Also, Leonardo has a deep experience in the energy sector with its technologies in aviation, including wind farms. Therefore, it gives us great pleasure to support this initiative with our established aerostructure engineering know-how and capabilities.”
“WindRunner must operate safely in a wide range of operating environments,” said AFuzion CEO Vance Hilderman. “And the urgency of the climate crisis demands that it move systematically through the certification process so that it can enter into service. AFuzion is eager to bring our capabilities to bear to support WindRunner’s progress from design all the way through to deployment.”
Aerospace Can Help Make Renewables Viable and Climate Goals Achievable
“WindRunner is exciting and consequential,” said Lundstrom, “not only because of the scope of the project but also because of its critical importance to the viability and the economics of renewable energy and society’s ability to meet our growing need for power while achieving our climate goals. Our partnership with Aernnova, Leonardo and AFuzion will enable us to deliver on that promise, fulfill our mission, and achieve a significant impact on renewables.”
About Radia
Radia is an energy company building a unique aerial transportation solution, the WindRunner, to radically expand the scope and scale of the onshore wind energy industry. Simultaneously, Radia is developing a world-class portfolio of wind energy projects to leverage this solution and partnering with the world’s largest energy and industrial companies to support their energy transition plans. This unique combination of capabilities allows Radia to bring together the ecosystem of stakeholders and partners to enable GigaWind – the largest onshore wind turbines manufactured by our partners deployed to more places to deliver differentiated low-cost clean electricity and, correspondingly, green molecules and synthetic fuels. Radia has been selected both as a World Economic Forum Global Unicorn and as an Endeavor Entrepreneur in their competitive International Selection Panel process. For more information: www.radia.com.
About Aernnova
Aernnova is a leading company specialized in the design, manufacturing, maintenance, and services of aerostructures and their components such as wings, empennages, fuselages, stabilizers, bulkheads, doors and moving surfaces for the world's leading aircraft manufacturers. Aernnova is a company committed to sustainability, technological development and digitization. Headquartered in Spain, Aernnova is among the world's leading Tier 1 aerostructures suppliers with a global presence through its manufacturing and engineering facilities in Spain, U.K., U.S.A., Portugal, Mexico and Brazil. More information about Aernnova can be found in: www.aernnova.com
About Leonardo
Leonardo is an international industrial group, among the main global companies in Aerospace, Defence, and Security (AD&S). With 53,000 employees worldwide, the company approaches global security through the Helicopters, Electronics, Aircraft, Cyber & Security and Space sectors, and is a partner on the most important international programmes, within these sectors, such as Eurofighter, NH-90, FREMM, GCAP, and Eurodrone. Leonardo has significant production capabilities in Italy, the UK, Poland, and the USA. Leonardo utilises its subsidiaries, joint ventures, and shareholdings, which include Leonardo DRS (72.3%), MBDA (25%), ATR (50 %), Hensoldt (22.8%), Telespazio (67%), Thales Alenia Space (33%), and Avio (29.6%). Listed on the Milan Stock Exchange (LDO), in 2023 Leonardo recorded new orders for €17.9 billion, with an order book of €39.5 billion and consolidated revenues of €15.3 billion. Included in the MIB ESG index, the company has also been part of the Dow Jones Sustainability Indices (DJSI) since 2010. More information about Leonardo can be found in: www.leonardo.com
About AFuzion
AFuzion specializes in avionics certification training and consulting, providing comprehensive solutions to help companies navigate complex regulatory requirements. With a focus on DO-254, AC 20-152A, and A(M)C 20-152A compliance, AFuzion's expert team offers invaluable guidance and training to ensure the development of reliable and safe avionics hardware.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718714101/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
